- Daxor (NASDAQ:DXR) is up 2% in response to new research supporting the value proposition of its BVA-100 test. The results were presented at Society of Critical Care Medicine Congress in San Diego.
- Recent studies showed 97% agreement between one (BVA-100) and five blood draws in critically ill patients and that BVA-100 was the most accurate way to establish blood volume.
- Reducing blood sampling will result in more rapid reporting of test results with a corresponding reduction in the quantity of blood sampled, technician time and costs.
- BVA-100 Blood Volume Analyzer, is the first instrument approved by the FDA to provide rapid direct measurement of a patient’s blood volume.